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The aim of this study was to investigate the effects of sodium bicarbonate (NaHCO3) on 4 km 
cycling time trial (TT) performance when individualised to a predetermined time to peak blood 
bicarbonate (HCO3-). Eleven male trained cyclists volunteered for this study (height 1.82 ± 
0.80 m, body mass (BM) 86.4 ± 12.9 kg, age 32 ± 9 years, peak power output (PPO) 382 ± 22 
W). Two trials were initially conducted to identify time to peak HCO3- following both 0.2 g.kg-
1 BM (SBC2) and 0.3 g.kg-1 BM (SBC3) NaHCO3. Thereafter, on three separate occasions 
using a randomized, double-blind, crossover design, participants completed a 4 km TT 
following ingestion of either SBC2, SBC3, or a taste-matched placebo (PLA) containing 0.07 
g.kg-1 BM sodium chloride (NaCl) at the predetermined individual time to peak HCO3-. Both 
SBC2 (-8.3 ± 3.5 s; p <0.001, d =0.64) and SBC3 (-8.6 ± 5.4 s; p =0.003, d =0.66) reduced the 
time to complete the 4 km TT, with no difference between SBC conditions (mean difference = 
0.2 ± 0.2 s; p =0.87, d =0.02). These findings suggest trained cyclists may benefit from 
individualising NaHCO3 ingestion to time to peak HCO3- to enhance 4 km TT performance.  














Competitive cycling is reflective of high-intensity exercise, particularly in events such as the 2 
individual and team pursuit, which entails completion of a 4 km time trial (TT). The typical 3 
duration of this event ranges between 4 (world record times) and 7 min (recreational riders), 4 
and because of this, a large energy supply is provided by anaerobic glycolysis (Gastin, 2001). 5 
With such a demand an exponential accumulation of metabolites including inorganic 6 
phosphate, hydrogen ions (H+), and lactate occurs (Westerblad et al., 2002; Allen et al., 2008). 7 
Due to the inverse relationship between H+ and pH, this process causes metabolic acidosis and 8 
results in a decrease in blood and muscle pH (Allen et al., 2008). Whilst there is no singular 9 
mechanism of peripheral fatigue, perturbations to acid base balance have been implicated to 10 
inhibit enzyme activity (e.g. glycogen phosphorylase) and calcium ion (Ca2+) cross-bridge 11 
binding (Fitts, 2008, 2016). Preventative strategies such as the ingestion of nutritional 12 
ergogenic aids may therefore be beneficial to mitigate such local acid-base disturbances in 13 
active musculature (Christensen, Shirai, Ritz, & Nordsborg, 2017; Matson & Tran, 1993).  14 
 15 
Ingestion of sodium bicarbonate (NaHCO3), a known buffering agent, can reinforce acid base 16 
balance by producing a state of metabolic alkalosis (increased pH and HCO3-) (McNamara & 17 
Worthley, 2001). Increases in pH typically result in a greater efflux of H+ and lactate from 18 
active musculature into extracellular compartments, due to a greater intra-extracellular 19 
gradient, whilst elevated HCO3- can be utilised to buffer against H+ within extracellular 20 
compartments (Bishop, Edge, Davis and Goodman, 2004). The resulting effect is more work 21 
completed during exercise of high intensities, which in turn, will improve exercise capacity or 22 
performance (Bishop et al., 2004; Marx et al., 2002). It is therefore important to heighten the 23 
level of blood alkalosis via changes in pH and HCO3- prior to exercise (Gough, Deb, Sparks & 24 
McNaughton, 2017a; Jones et al., 2016). Common practice is to prescribe NaHCO3 between a 25 
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set time of between 60 and 90 mins for all participants (Carr, Hopkins and Gore, 2011; Price 26 
and Singh, 2008; Siegler et al., 2009). In a recent study, however, it was reported time to peak 27 
HCO3- occurred between 40 and 125 min (Gough et al., 2017a), with a similar variation 28 
observed in other dose-response studies (Jones et al., 2016; Miller et al., 2016). Many 29 
participants may not therefore achieve peak alkalosis at the start of exercise, which might 30 
explain, in part, the lack of an ergogenic effect of NaHCO3 supplemented at 100 min (Correia-31 
Oliveira et al., 2017) and 150 min (Callahan, Parr, Hawley & Burke, 2017) in other 4 km 32 
cycling TT studies.  33 
 34 
In response to such variation in time to peak alkalosis it is recommended that either time to 35 
peak pH or HCO3- is predetermined prior to use for an exercise bout, as this accounts for the 36 
inter-individual variation commonly observed (McNaughton et al., 2016; Miller et al., 2016; 37 
Jones et al., 2016; Gough et al., 2017c). Indeed, preliminary studies to date have displayed 38 
ergogenic benefits of NaHCO3 individualised to a predetermined peak pH in cycling 39 
performance (Miller et al., 2016; Deb et al., 2017). Gough et al. (2017a) however, recently 40 
demonstrated greater reliability of time to peak HCO3- compared to time to peak pH with 41 
Intraclass Correlation Coefficient (ICC) analysis (r =0.94 vs. 0.71). It may therefore be more 42 
appropriate to determine the effects of NaHCO3 on HCO3- responses, particularly if the athlete 43 
wishes to achieve peak alkalosis consistently. Nonetheless, no study to date has investigated 44 
the potential ergogenic effects of NaHCO3 supplementation determined by a predetermined 45 
individual time to peak HCO3- on an exercise protocol reflective of competitive cycling such 46 
as a 4 km TT.  47 
 48 
Investigations into the ergogenic effects of individualising NaHCO3 to a predetermined time 49 
to peak pH have prescribed an amount of 0.3 g.kg-1 BM (Miller et al., 2016; Deb et al., 2017). 50 
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This is likely due to early research by McNaughton (1992) reporting a dose-dependent effect 51 
on performance, with 0.3 g.kg-1 BM NaHCO3 improving total work done (TWD) to a greater 52 
magnitude than 0.2 g.kg-1 during 60 s of maximal cycling; whilst meta-analyses have also 53 
shown a meaningful effect on exercise performance following 0.3 g.kg-1 BM NaHCO3 (Peart 54 
et al., 2012; Carr et al., 2011). Despite this, there is a paucity of literature investigating the 55 
dose-dependent ergogenic effects from smaller doses of NaHCO3 on exercise performance. 56 
The greater magnitude of effect between 0.3 g.kg-1 and 0.2 g.kg-1 BM NaHCO3 reported by 57 
McNaughton (1992) for instance, was non-significant and only considered one exercise 58 
duration/intensity and participant cohort (recreationally active). Furthermore, McKenzie, 59 
Coutts, Stirling, Hoeben and Kuzara (1986) reported a negligible 0.3% difference between 0.15 60 
g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3 in a cycling time to volitional exhaustion test at 125% 61 
VO2max. Based on such limited evidence, further research is warranted exploring the dose-62 
dependent effects of NaHCO3. 63 
 64 
A further concern of a 0.3 g.kg-1 BM NaHCO3 ingestion strategy is the commonly reported 65 
gastrointestinal (GI) discomfort symptoms such as stomach cramp, diarrhoea, and in extreme 66 
cases, vomiting, which can have major negative implications for exercise performance 67 
(Saunders et al., 2014; Gough et al., 2017a, 2017b). It is therefore important to maximise the 68 
potential ergogenic effect through attaining peak buffering capacity, whilst also managing the 69 
severity of (GI) discomfort. Given that smaller amounts of NaHCO3 (i.e. 0.2 g.kg-1 BM) are 70 
associated with lower instances and severity of GI discomfort (Gough et al., 2017a, 2017c), it 71 
may be prudent to suggest this amount is a better option practically to the athlete aiming to 72 




To heighten the likeliness of an ergogenic benefit and mitigate the severity of GI discomfort, 75 
0.2 g.kg-1 BM NaHCO3 individualised to a predetermined time to peak HCO3- may be suitable. 76 
Gough et al. (2017a) reported a 5.7 ± 0.9 mmol.l-1 increase of HCO3- following 0.2 g.kg-1 BM 77 
NaHCO3 using a time to peak HCO3- strategy, which is superior to the 3.9 ± 0.9 mmol.l-1 mean 78 
change reported in a meta-analysis following a standardised 0.3 g.kg-1 BM NaHCO3 dose (Carr 79 
et al., 2011). These changes in acid base balance following 0.2 g.kg-1 BM NaHCO3 are also 80 
close to the 6 mmol.l-1 increase purported to lead to an ergogenic effect on performance 81 
(Matson & Tran, 1993; Jones et al., 2016). These data combined, suggest 0.2 g.kg-1 BM 82 
NaHCO3 individualised to a pre-determined time to peak HCO3- achieves the required acid 83 
base balance changes that may improve performance, whilst also reducing the symptoms of GI 84 
discomfort. Despite this, no literature to date has investigated the dose-dependent effects (i.e. 85 
0.2 g.kg-1 vs. 0.3 g.kg-1 BM NaHCO3) on exercise performance when individualised to a 86 
predetermined time to peak HCO3-. The purpose of this study, therefore, was to investigate the 87 
effects of both 0.2 g.kg-1 BM (SBC2) and 0.3 g.kg-1 BM (SBC3) NaHCO3 individualised to a 88 
predetermined time to peak HCO3- on 4 km TT performance. We hypothesised that both SBC2 89 
and SBC3 would reduce the time required to complete the 4 km TT. 90 
 91 
Materials and Methods 92 
Participants  93 
A priori power calculation conducted using SPSS Sample Power 3 (IBM, Chicago, IL, USA) 94 
displayed a sample size of 11 would allow detection of a 3 s change with high statistical power 95 
(β = 0.80; 0.05 = α level). This set criterion was used to detect a difference between NaHCO3 96 
treatments (i.e. SBC2 vs. SBC3) and between SBC treatments and the placebo, as this is the 97 
typical difference required to determine medal positions for the men’s individual pursuit and 98 
similar events at Olympic Games (Christensen et al., 2017). Eleven male trained cyclists 99 
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therefore volunteered for this study (height 1.82 ± 0.8 m, body mass 86.4 ± 12.9 kg, age 32 ± 100 
9 years, peak power output (PPO) 382 ± 22 W) with a weekly training frequency of ≥3 times, 101 
for a total of ≥5 hours per week, and for a minimum of 2 years training experience, which was 102 
specifically in cycling. Based on these descriptors, participants met the criteria of ‘trained 103 
cyclist’ as described by De Pauw et al. (2013). Participants were also excluded if they had 104 
ingested any nutritional buffers (such as beta alanine) in the prior 6 months of the study. Ethical 105 
approval was obtained from the Departmental Research Ethics Committee and each participant 106 
provided written informed consent prior to experimental testing.  107 
 108 
Experimental overview  109 
Participants visited the laboratory on six occasions in a randomised, crossover and double blind 110 
designed study (2 x identification of peak blood HCO3-, 3 x cycling TT’s). Constraints on 111 
ingestion of alcohol and participation in any strenuous/unaccustomed exercise were in place 112 
24 hours prior to each trial. Caffeine was also prohibited 12 hours prior to any trial. Written 113 
logs of nutritional intake were taken, with intake from the first trial replicated for subsequent 114 
trials. Participants visited the laboratory in a four-hour postprandial state and trials were 115 
conducted at the same time of day to account for circadian rhythms (Reilly, 1990). 116 
Experimental trials were separated by at least three days to allow acid base balance variables 117 
to return to normal resting concentrations (Siegler et al., 2009).  118 
 119 
Identification of time to peak blood bicarbonate 120 
On two separate occasions participants ingested either 0.2 g.kg-1 BM NaHCO3 (SBC2) or 0.3 121 
g.kg-1 BM NaHCO3 (SBC3) mixed with 400 ml of water and 50 ml double strength and sugar-122 
free blackcurrant cordial to identify time to peak blood HCO3- and pH. Whilst quietly resting 123 
and seated, finger prick capillary blood samples were collected in a 100µl sodium heparin-124 
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coated glass clinitube every 10 min for analysis of blood HCO3- and pH over a 120 min period 125 
using a blood gas analyser (ABL800 BASIC, Radiometer Medical Ltd. Denmark). The highest 126 
HCO3- value was used as a determination of time to peak HCO3- and this determined the timing 127 
of ingestion for experimental trials. Supplementation of NaHCO3 was double blinded and 128 
randomised (block randomisation), as a laboratory technician outside of the research group 129 
prepared the NaHCO3. Likewise, the time to peak HCO3- was determined by researchers 130 
outside of the study and the participant was not informed of their time to peak to ensure the 131 
double blind nature of the study. For the PLA condition, a time to peak HCO3- was used from 132 
either SBC2 or SBC3.  133 
 134 
Four-kilometre cycling protocol, blood measures and perceptual measures 135 
The next visit involved a familiarisation to the 4 km cycling TT on a Velotron cycle ergometer 136 
(Velotron, RacerMate Inc., USA) interfaced with Velotron coaching software (RacerMate Inc., 137 
USA). This ergometer has displayed high test-retest reliability with excellent ICC values of 138 
between r =0.90 to 0.96, p <0.01 for mean power in TT events (Astorino, 2011; Costa, 139 
Guglielmo & Paton, 2017). Participants selected a preferred handlebar and saddle position, 140 
whilst they were also permitted to change gears freely throughout each TT using their preferred 141 
fixed gear ratios. These settings were then adopted for all subsequent trials. Strong verbal 142 
encouragement was provided throughout the TT and feedback on the distance covered and 143 
cadence was provided via the software (Stone et al., 2011), but time elapsed was blinded. Time 144 
to complete, mean power and mean speed was recorded for both the total distance and 0.5 km 145 
splits, along with heart rate (HR) every 0.5 km (Polar, T31, Finland). Blood measures for pH 146 
and HCO3- were taken pre-ingestion and post-exercise as per the previously described method. 147 
A 5µl sample for blood lactate (BLa) was also taken at the same respective time points (Lactate 148 
Pro 2, Arkray, Japan). Ratings of perceived exertion (6-20; Borg, 1982) for the whole body 149 
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(RPEO), legs (RPEL), and affective perceptions of work rate (11-point bipolar scale with +5 150 
representing ‘very good’ and -5 representing ‘very bad’) were recorded every 1 km (Thomas 151 
et al., 2015). This procedure was repeated another three times, with the exception that either 152 
0.2 g.kg-1 BM NaHCO3 (SBC2), 0.3 g.kg-1 BM NaHCO3 (SBC3) or a taste matched placebo 153 
(PLA) containing 0.07 g.kg-1 BM sodium chloride (NaCl) was ingested, after baseline measures 154 
were taken. Participants then sat quietly rested until their respective predetermined time to peak 155 
HCO3-, at which point a further blood sample was taken. Treatments were administered in a 156 
double-blind manner, and for PLA treatments, a time to peak HCO3- time frame from an SBC 157 
treatment was selected randomly by a researcher outside of the study to maintain the double-158 
blind design. Following ingestion, and up to the individuals respective time to peak HCO3-, GI 159 
discomfort was measured using a visual analogue scale (VAS) every 10 min, as per previous 160 
studies (Miller et al., 2016; Gough et al., 2017a). 161 
 162 
Statistical analysis 163 
Assessed variables were analysed using both Shapiro-Wilk tests and standard graphical 164 
methods for normality, whilst a Mauchly test was used for homogeneity and 165 
variance/sphericity.  A paired sampled t-test was used to assess the severity and time to peak 166 
GI discomfort between SBC treatments. Both mean power and speed were analysed using a 167 
repeated measures ANOVA. Otherwise, a two-way repeated measures ANOVA (e.g. condition 168 
x each 0.5 km segment/time point) was used and where either interactions or main effects were 169 
observed, Bonferroni corrected posthoc pairwise comparisons were carried out. Where main 170 
effects or interactions were observed, partial eta squared (Pη2) effect size is reported. Between 171 
treatment effect sizes (d) were calculated using the difference in means divided by the pooled 172 
SD of the compared trials (Nagakawa & Cuthill, 2007), however with a Hedge’s g bias 173 
correction to account for the sample size in this study (Lakens, 2013). All effect size 174 
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interpretations were considered as trivial (<0.20), small (0.20-0.49), moderate (0.50-0.79) or 175 
large (≥0.80) (Cohen, 1988). Intraclass Correlation Coefficients (ICC) were used to determine 176 
the reproducibility of blood metabolites (i.e. time to peak HCO3- and pH) following SBC 177 
conditions and are reported with r value and significance value (p value). Interpretation of 178 
reproducibility was determined by the respective r value with categories of poor (<0.40), fair 179 
(0.40-0.59), good (0.60-0.74) and excellent (>0.74). Data are presented as mean ± SD with 180 
95% confidence intervals (CI) unless otherwise stated. Statistical significance was set at p 181 
<0.05 and data were analysed using SPSS v22 for Windows (SPSS Inc., Chicago, IL, USA). 182 
 183 
Results 184 
Performance responses for all participants (n =11)  185 
Faster mean completion times (Figure 1) by 8.3 ± 3.4 s were observed following SBC2 (p < 186 
0.001, CI = 12.0, 4.7, d = 0.64) and by 8.6 s ± 5.2 s following SBC3 compared to PLA, 187 
respectively (p =0.003, CI = 14.2, 3.0, d =0.66). There was no difference between SBC2 and 188 
SBC3 (374.0 ± 13.3 vs. 373.7 ± 13.3 s, p =0.87, CI = -3.0, 3.7, d =0.02; Figure 1). 189 
 190 
**Figure 1 near here** 191 
 192 
A 16 ± 13 W (+5.7%) increase in mean power was observed following SBC2 (304 ± 28 W, p 193 
=0.02, CI = 2.6, 30.3, d =0.62), while in SBC3 an increase of 16 ± 15 W (+5.9%) was observed 194 
(304 ± 31 W, p =0.03, CI = 1.1, 32.9, d =0.58; Figure 2a) compared to PLA (287 ± 25 W). 195 
There was no difference between SBC2 and SBC3 (p =0.90, CI = -10.2, 9.1, d =0.01). 196 
Following SBC2, a 0.9 ± 0.6 km.h-1 (+2.4%) increase in mean speed was observed compared 197 
to PLA (38.6 ± 1.4 vs. 37.7 ± 1.1 km.h-1, p =0.008, CI = 0.2, 1.6, d =0.69). Similarly, a 0.8 ± 198 
0.6 km.h-1 (+2.0%) increase in mean speed was observed following SBC3 (38.4 ± 1.3, p =0.02, 199 
11 
 
CI = 0.1, 1.4, d =0.56), whilst there was no difference between SBC conditions (p =0.42, CI = 200 
-0.3, 0.6, d =0.14; Figure 2b).  201 
 202 
** Figure 2 near here** 203 
 204 
Performance responses for participants who suffered gastrointestinal (GI) discomfort (n =8) 205 
Despite the occurrence of GI discomfort, SBC2 improved performance by 9.0 ± 3.8 s in SBC2 206 
(p =0.001, CI = 4.5, 13.5, d = 0.68) and 8.9 ± 6.1 s in SBC3 (p =0.02, CI = 1.7, 16.2, d = 0.68) 207 
compared to PLA. Only one participant failed to improve performance (0.1 s difference vs. 208 
PLA), whilst three participants improved by less than the 3 s threshold that was set in the priory 209 
power calculation for a meaningful effect (range = 2-2.6 s improvement vs. PLA).  210 
 211 
Blood metabolite responses 212 
Absolute peak change in HCO3- from baseline was 5.5 ± 0.7 in SBC2 and 6.5 ± 1.3 mmol.l-1 in 213 
SBC3 which was not significantly different (p =0.07; d =0.92).  Peak HCO3- occurred within a 214 
range of between 40 to 110 mins in SBC2 (mean 62 ± 20 min, CV: 33%), and between 40 to 215 
100 min in SBC3 (mean 73 ± 20 min, CV: 27%; Figure 3).  216 
 217 
**Figure 3 near here** 218 
 219 
The change from baseline to the peak pH was not significantly different between SBC 220 
conditions (p =0.13, d =0.75; SBC2 =0.07 ± 0.02, SBC3 =0.09 ± 0.03). In subsequent cycling 221 
trials (i.e. 4km TT’s) good reproducibility was observed for absolute mean change from 222 
baseline in pH following both SBC2 (+0.06; ICC r =0.67, p =0.026) and SBC3 (+0.06; r =0.65, 223 
p =0.040).  Greater reproducibility was observed for absolute mean change in HCO3- however, 224 
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displaying excellent reliability in both SBC2 (+4.9 mmol.l-1; r =0.86, p =0.002) and SBC3 225 
(+5.6 mmol.l-1; r =0.88, p <0.001).  226 
 227 
In the cycling trials, a time × treatment interaction was observed for pH (p =0.048, Pη2 =0.285) 228 
whereby pH was +0.07 ± 0.02 (+0.9%) greater at time to peak (figure 4a) for SBC2 (7.46 ± 229 
0.03; p <0.001, CI = 0.09, 0.04, d =2.64) and 0.08 ± 0.02 (+1%) greater for SBC3 (7.47 ± 0.02; 230 
p <0.001, CI = 0.09, 0.05, d =3.85) compared to PLA (7.39 ± 0.02). There was no difference 231 
between SBC2 and SBC3 (p =0.69, CI = -0.3, 0.1; d =0.38). A time × treatment interaction was 232 
observed for HCO3- (p <0.001, Pη2 =0.796), with values greater following supplementation of 233 
NaHCO3 (Figure 4b). At time to peak HCO3-, SBC2 was 5.0 mmol.l-1 ± 1.0 mmol.l-1 (+17.6%) 234 
(28.6 ± 1.1 mmol.l-1; p <0.001, CI = 6.0, 4.1, d =5.22) and SBC3 was 5.9 ± 1.1 mmol.l-1 235 
(+20.0%) (29.5 ± 1.0 mmol.1-1; p <0.001, CI = 6.9, 5.0, d =6.58) greater than PLA (23.6 ± 0.7 236 
mmol.l-1). There was no difference between SBC2 and SBC3 (p =0.34, CI = -2.3, 0.6, d =0.82). 237 
 238 
Post exercise HCO3- was +1.8 ± 1.3 mmol.l-1 (+12.3%) greater for SBC2 (16.0 ± 2.2 mmol.l-1; 239 
p =0.004, CI = 2.9, 0.6, d =0.79), and +1.5 ± 1.3 mmol.l-1 (+10.9%) greater for SBC3 (15.8 ± 240 
2.7 mmol.l-1; p =0.01, CI = 2.7, 0.4, d =0.62) compared to PLA (14.2 ± 2.2 mmol.l-1). There 241 
was a main effect for treatment in HCO3- change during exercise (p <0.001, Pη2 =0.714), 242 
whereby the change in HCO3- was 3.3 ± 1.8 mmol.l-1 (+25.9%) greater following SBC2 (12.7 243 
± 2.6 mmol.l-1; p =0.001, CI = 4.9, 1.6, d =1.37) and 4.4 ± 1.7 mmol.l-1 (+31.7%) greater for 244 
SBC3 (13.8 ± 2.7 mmol.l-1; p <0.001, CI = 5.9, 2.8, d =1.78) compared to PLA (9.4 ± 2.0 245 
mmol.l-1). There was no difference between SBC conditions (p =0.59, CI = -1.2, 3.3; d =0.40). 246 
A main effect for time was observed for BLa (p <0.001, Pη2 =0.957) with all conditions 247 
displaying greater post-exercise BLa compared to pre-exercise (Figure 4c). Post-exercise, a 248 
time × treatment interaction was observed for BLa (p <0.001, Pη2 =0.577) as SBC2 was +3.7 249 
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± 2.8 mmol.l-1 (+22.5%) greater than PLA (16.1 ± 3.4 vs. 12.5 ± 2.7 mmol.l-1, p =0.006, CI = 250 
1.1, 5.8, d =1.13; Figure 4c), with SBC3 greater by +3.7 ± 2.4 mmol.l-1 (+22.7%)  (16.1 ± 3.4 251 
mmol.l-1; p =0.002, CI = 1.5, 5.8, d =1.13). No differences between SBC conditions were 252 
evident for post-exercise BLa (p =0.61, CI = -2.3, 2.2; d =0.01).  253 
 254 
*Figure 4 near here** 255 
 256 
Gastrointestinal (GI) discomfort  257 
Four participants reported symptoms of belching and stomach bloating in SBC2, compared to 258 
seven participants reporting symptoms of belching, stomach cramp, bowel urgency and 259 
diarrhoea in SBC3. There was no significant difference in severity of GI discomfort between 260 
SBC treatments (SBC2 =1.4 ± 1.5 vs. SBC3 =4.6 ± 3.6; p =0.10), although a large effect size 261 
was evident (d =0.88). Similarly, time to peak GI discomfort was not significantly different 262 
between SBC treatments (SBC2 =20 ± 24 vs. SBC =43 ± 31min, p =0.13), although revealed 263 
a large effect size (d  =0.80).  264 
 265 
Heart rate (HR), ratings of perceived exertion (RPE) and affective perceptions of work rate 266 
scale 267 
Heart rate was unaffected by NaHCO3 ingestion as no time × treatment interaction was 268 
observed (p =0.56, Pη2 =0.055). There was a main effect for time (p <0.001, Pη2 =0.977) for 269 
HR and mean data combined from all treatments displayed HR at 500m was 144 ± 3 b.min-1, 270 
compared to 171 ± 2 b.min-1 at 4 km, respectively. A main effect for time was observed for 271 
RPEO (p <0.001, Pη2 =0.849), as at 1 km RPEO was 14 ± 1 compared to 17 ± 1 at 4 km, although 272 
no time × treatment was apparent (p =0.31, Pη2 =0.109). A main effect for time was observed 273 
for RPEL (p <0.001, Pη2 =0.657), as at 1 km RPEL was 15 ± 1 compared to 18 ± 0 at 4 km, 274 
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although no time × treatment interaction was evident (p =0.73, Pη2 =0.085). Affective 275 
perceptions of work rate revealed no time × treatment interaction (p =0.38, Pη2 =0.099) or main 276 
effect for time (p =0.92, Pη2 =0.020).  277 
 278 
Discussion 279 
In agreement with our hypothesis, this study reports that both 0.2 g.kg-1 (SBC2) and 0.3 g.kg-1 280 
BM (SBC3) NaHCO3 improves 4 km TT cycling performance in trained cyclists when 281 
individualised to a predetermined time to peak HCO3-. Time to complete the time trial was 282 
2.2% faster in SBC2 and 2.3% in SBC3 compared to PLA, whilst there was also no statistical 283 
difference between SBC conditions suggesting both amounts are appropriate to enhance this 284 
type of exercise performance. Combining such performance effects with the reduced instances 285 
and severity of GI discomfort following 0.2 g.kg-1 BM NaHCO3 however, the present study 286 
findings suggest this amount may be more attractive to the athlete in a practical setting.   287 
 288 
The findings of the present study contrast that of two recent studies reporting no effect of 289 
NaHCO3 on 4 km TT performance (Callahan et al., 2017; Correia-Oliveira et al., 2017). Indeed, 290 
Callahan et al. (2017) reported a ‘possibly trivial’ effect and Correia-Oliveira (2017) reported 291 
no significant supplement interaction in ANOVA analysis following 0.3 g.kg-1 BM NaHCO3. 292 
In comparison, the present study displayed a statistically significant effect and a moderate 293 
effect size for both SBC2 and SBC3. This ergogenic effect was most likely realised due to 294 
supplementing NaHCO3 to a predetermined time to peak HCO3-, as this would have ensured 295 
peak bioavailability of HCO3- at the commencement of exercise. In particular, the increase in 296 
HCO3- following the SBC2 treatment of the present study was similar, whilst the SBC3 297 
treatment was superior, to the values reported in the aforementioned studies with 0.3 g.kg-1 BM 298 
NaHCO3 (SBC2 = 4.9 to 5.5 mmol.l-1, SBC3 = 5.6 to 6.5 mmol.l-1 vs. Callaghan et al. = +3 299 
15 
 
mmol.l-1 vs. Correia-Oliveira et al. = +5mmol.l-1). Based on this evidence, it is therefore more 300 
appropriate to identify time to peak HCO3- prior to the use in exercise to elicit ergogenic effects 301 
on performance. A consideration, however, is that identifying time to peak HCO3- presents a 302 
logistical challenge, as this would require a visit to a laboratory or access to a portable blood 303 
gas analyser. 304 
  305 
A unique finding of the present study was the lack of a dose-dependent effect on exercise 306 
performance, with SBC3 improving performance to a similar magnitude as SBC2. These 307 
findings are in contrast to McNaughton (1992), reporting 0.3 g.kg-1 BM NaHCO3 improved 308 
TWD greater than 0.2 g.kg-1 BM NaHCO3 during 60 seconds of maximal cycling compared to 309 
a placebo. The negligible 0.1% difference observed between SBC2 and SBC3 are more in 310 
agreement with the findings of McKenzie et al. (1986) reporting a 0.3% difference between 311 
0.15 g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3. Individual performance responses did reveal that 312 
three participants improved to a greater extent in SBC2 compared to SBC3, whilst two 313 
participants improved to a greater extent in SBC3 compared to SBC2 based on the 3 s cut off 314 
from the prior power calculation. These data combined suggest lower amounts of NaHCO3 (i.e. 315 
0.2 g.kg-1 BM) are likely to be sufficient to enhance exercise of this duration and intensity, 316 
although athletes should trial each dose prior to use in competition to evaluate which amount 317 
of NaHCO3 provides a larger ergogenic benefit. Likewise, considering the potential for the 318 
onset of GI discomfort, athletes who are susceptible to such symptoms should conduct a 319 
risk:benefit analysis of NaHCO3 supplementation.  320 
 321 
It is purported that mitigating the severity of GI discomfort is important to obtain a performance 322 
benefit following NaHCO3 supplementation, as Saunders et al. (2014) reported a significant 323 
effect on performance only upon the removal of participants who suffered from GI discomfort. 324 
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The present study findings contrast this by reporting a significant 2.3% improvement following 325 
both SBC2 and SBC3, despite the occurrence of mild to moderate GI discomfort. Reasons for 326 
this may be due to the good tolerance of NaHCO3 in our participant cohort, although it is 327 
difficult to compare with the work of Saunders et al. (2014) as no explicit statistical analysis 328 
on GI discomfort is available. Nonetheless, there may still be a relationship between GI 329 
discomfort and performance, as for instance, participant 8 in the present study suffered from 330 
moderate diarrhoea and bowel urgency in SBC3 and no improvement in performance was 331 
observed (0.1 s). While performance in SBC2 was improved by 8.9 s in the same participant 332 
when no instances of GI discomfort occurred. Combining this finding with other investigations 333 
where participants have self-withdrawn, or have been withdrawn by the research team due to 334 
the severity of GI discomfort, the responses from NaHCO3 still warrant observation in training 335 
prior to use in competition (Gough et al., 2017a, 2017b; Jones et al., 2016). Nonetheless, 336 
smaller amounts of NaHCO3 may be an attractive solution to the athlete to reduce the severity 337 
of GI discomfort symptoms whilst still providing ergogenic effects to exercise performance.  338 
 339 
The enhancements of acid base balance following NaHCO3 are the most likely mechanism for 340 
an improved performance in the present study, as both SBC2 and SBC3 raised HCO3- and pH 341 
significantly compared PLA. An increase in extracellular HCO3- is suggested to increase H+ 342 
efflux during exercise due to the up-regulation of the lactate/H+ cotransporter, leading to 343 
increased provision of anaerobic energy contribution (Marx et al., 2002). The change in HCO3- 344 
was superior in both SBC2 (+25.9% vs. PLA) and SBC3 (+31.7% vs. PLA) whilst post-345 
exercise blood lactate was also significantly higher (~15%) in the SBC conditions. These 346 
changes in blood acid base balance and BLa are indicative of exercise at higher exercise 347 
intensities in the SBC conditions and hence, improved performance. Furthermore, between 348 
SBC conditions there were minimal differences in respect of blood metabolites changes prior 349 
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to, or during exercise. This provides an explanation why there were no dose-dependent effects 350 
on performance in the present study. 351 
 352 
Conclusion 353 
Ingestion of NaHCO3 individualised to time to peak HCO3- improves 4 km TT cycling 354 
performance in trained cyclists. Ingestion of both 0.2 g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3 355 
equally increase buffering capacity and subsequently provided ergogenic benefits to exercise 356 
performance. No difference was observed between SBC conditions; therefore, athletes can 357 
plausibly use a lower amount of NaHCO3 (i.e. 0.2 g.kg-1 BM) particularly if they are susceptible 358 
to the onset GI discomfort. Future research should investigate the dose-dependent effects of 359 
both 0.2 g.kg-1 BM and 0.3 g.kg-1 BM NaHCO3 during exercise of different intensities and 360 
durations.  361 
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